Distribution of ciprofloxacin-resistance genes among ST131 and non-ST131 clones of Escherichia coli isolates with ESBL phenotypes isolated from women with urinary tract infection

• Published in: Iranian journal of microbiology Vol. 13; no. 3; pp. 294 - 302
• Main Authors: Rasoulinasab, Masoumeh, Shahcheraghi, Fereshteh, Feizabadi, Mohammad Mehdi, Nikmanesh, Bahram, Hajihasani, Azade, Aslani, Mohammad Mehdi
• Format: Journal Article
• Language: English
• Published: Iran Tehran University of Medical Sciences 01.06.2021
• Subjects: beta-lactamase ctx-m-15; fluoroquinolones; multilocus sequence typing; Original; urinary tract infections; uropathogenic escherichia coli; Fluoroquinolones; Beta-lactamase CTX-M-15; Uropathogenic Escherichia coli; Urinary tract infections; Multilocus sequence typing
• ISSN: 2008-3289; 2008-4447
• DOI: 10.18502/ijm.v13i3.6389

sequence type 131 (ST131) is associated with extended-spectrum beta-lactamase (ESBL) production and fluoroquinolone resistance. This study aimed to investigate the prevalence of ST131, ESBL, and plasmid-mediated quinolone resistance (PMQR) genes in the ciprofloxacin-resistant (CIP ) and ESBL producers from women with UTI. The CIP-resistant ESBL producing (CIP /ESBL ) isolates were screened for ST131-by specific PCR of and . The ESBL and PMQR genes were screened by single PCR. The ST131 and non-ST131 isolates were selected to determine the mutations of and using PCR and sequencing, and also their genetic background by the Pasteur-MLST scheme. Overall, 55% (33/60) CIP /ESBL isolates were identified as ST131 (94% O25b-ST131). Resistance rate to ampicillin-sulbactam (70%), aztreonam (97%) and gentamicin (61%), the prevalence of (66%), (82%), the profile of (30%), and the double mutation in the was significantly higher in ST131 than non- ST131 isolates. The coexistence of PMQR and ESBL genes was found in more than 50% of ST131 and non-ST131 isolates. ST131 isolates differentiated into PST43 and PST506. Management of women with UTI caused by the CIP /ESBL isolates (ST131) co-harbored PMQR, ESBL, and chromosomal mutations, is important for their effective therapy.